Evidence map›Paper›PMID 27980395›Full record

ArticlePatient preference and adherence2016

Utility of the Morisky Medication Adherence Scale in gout: a prospective study.

Csl Tan, G G Teng, K J Chong, P P Cheung, Ayn Lim, H L Wee, A Santosa

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Patient preference and adherence, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Validation of the Test of Adherence to Inhalers (TAI) among Taiwanese Patients with Chronic Obstructive Pulmonary Disease.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Improving adherence to gout therapy: an expert review.Therapeutics and clinical risk management · 2018
    Review
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Csl TanUniversity Medicine Cluster, Division of Rheumatology, National University Health System.
G G TengUniversity Medicine Cluster, Division of Rheumatology, National University Health System; Department of Medicine, Yong Loo Lin School of Medicine.
K J ChongDepartment of Medicine, Yong Loo Lin School of Medicine.
P P CheungUniversity Medicine Cluster, Division of Rheumatology, National University Health System; Department of Medicine, Yong Loo Lin School of Medicine.
Ayn LimUniversity Medicine Cluster, Division of Rheumatology, National University Health System; Department of Medicine, Yong Loo Lin School of Medicine.
H L WeeDepartment of Pharmacy, Faculty of Science; Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
A SantosaUniversity Medicine Cluster, Division of Rheumatology, National University Health System; Department of Medicine, Yong Loo Lin School of Medicine.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe outcomes of any chronic illness often depend on patients' adherence with their treatment. A tool is lacking to assess adherence in gout that is standardized, allows real-time feedback, and is easy to understand.

objectiveWe set out to evaluate the utility of the 8-item Morisky Medication Adherence Scale (MMAS-8) in monitoring medication adherence in a multiethnic Asian gout cohort on urate-lowering therapy (ULT).

methodsThis cohort study recruited patients with gout where baseline and 6-monthly clinical data, self-report of adherence, and health status by Gout Impact Scale (GIS) and EuroQoL-5 dimension 3 levels were collected. Those who received at least 9 months of ULT were analyzed. Convergent and construct validities of MMAS-8 were evaluated against medication possession ratio (MPR) and known groups, clinical outcomes, and patient-reported outcomes. Internal consistency and test-retest reliability were assessed using Cronbach's alpha and intraclass correlation coefficient (ICC), respectively.

resultsOf 91 patients, 92.3% were male, 72.5% Chinese with mean age 53.5 years. MMAS-8 (mean 6.17) and MPR (mean 96.3%) were poorly correlated (

conclusionMMAS-8 had limited construct validity in assessing medication adherence to ULT in our gout patients. Nevertheless, it identified patients bothered or worried about ULT side effects, and those with underlying anxiety or depression, for whom targeted education and coping support may be useful.

Indexed as

8-item Morisky Medication Adherence ScalegoutMMAS-8serum urateSingaporeurate-lowering therapy

Identifiers

PMID27980395
PMCPMC5144895

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.